APA (7th ed.) Citation

Gerometta, M., Henderson, R. D., Friend, R., Cooper, L. T., Zhao, J., Boyd, A. W., & Bartlett, P. F. (2025). Evaluation of NUN-004, a Novel Engineered Ephrin Antagonist, in Healthy Volunteers and Patients with Amyotrophic Lateral Sclerosis: A Phase I/Ib, Open-Label, Escalating Dose and Extended Access Study: NUN-004 in Patients with Amyotrophic Lateral Sclerosis: M. Gerometta et al. Clinical Drug Investigation, 45(1), 17. https://doi.org/10.1007/s40261-024-01410-x

Chicago Style (17th ed.) Citation

Gerometta, Michael, Robert D. Henderson, Richard Friend, Leanne T. Cooper, Jing Zhao, Andrew W. Boyd, and Perry F. Bartlett. "Evaluation of NUN-004, a Novel Engineered Ephrin Antagonist, in Healthy Volunteers and Patients with Amyotrophic Lateral Sclerosis: A Phase I/Ib, Open-Label, Escalating Dose and Extended Access Study: NUN-004 in Patients with Amyotrophic Lateral Sclerosis: M. Gerometta Et Al." Clinical Drug Investigation 45, no. 1 (2025): 17. https://doi.org/10.1007/s40261-024-01410-x.

MLA (9th ed.) Citation

Gerometta, Michael, et al. "Evaluation of NUN-004, a Novel Engineered Ephrin Antagonist, in Healthy Volunteers and Patients with Amyotrophic Lateral Sclerosis: A Phase I/Ib, Open-Label, Escalating Dose and Extended Access Study: NUN-004 in Patients with Amyotrophic Lateral Sclerosis: M. Gerometta Et Al." Clinical Drug Investigation, vol. 45, no. 1, 2025, p. 17, https://doi.org/10.1007/s40261-024-01410-x.